ArticleJournal of the American Heart Association2026
Timeliness of Care for Transferred and Directly Admitted Patients With Anticoagulation-Associated Intracerebral Hemorrhage.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Accelerating Reversal and Refining Transfer Are Imperative for Anticoagulation-Associated Intracerebral Hemorrhage.Journal of the American Heart Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with anticoagulation-associated intracerebral hemorrhage are often transferred from the presenting hospital to one with additional resources. Understanding differences in timeliness and care, including anticoagulant reversal, between transfer and direct admissions may identify quality improvement opportunities.
methodsThis cross-sectional study included all hospitals in the American Heart Association GWTG-Stroke (Get With The Guidelines-Stroke) registry where anticoagulant reversal was administered (2015-2021). Patients with anticoagulation-associated intracerebral hemorrhage presenting within 24 hours of onset and with information on prior AC treatment were included. Outcomes included functional score at discharge, in-hospital death/discharge to hospice, discharge ambulatory status, discharge destination, and length of stay.
resultsOf 30 590 patients with AC-ICH, 14 882 (48.6%) were transfers. Symptom onset to AC reversal was longer for transfer patients who received anticoagulant reversal at the admitting hospital versus direct-admission patients (512 [interquartile range 328-840] versus 273 [interquartile range, 153-579] minutes; absolute standardized mean difference, 75.9%). Transfer patients had milder stroke severity on admission versus direct-admission patients on the basis of National Institute of Health Stroke Scale (7 [interquartile range, 2-19] versus 11 [interquartile range, 3-22]; absolute standardized mean difference, 21.2%) and intracerebral hemorrhage scores (1.81±1.36 versus 2.02±1.47; absolute standardized mean difference, 13.7%). In an adjusted logistic regression model, transfer patients had lower odds of in-hospital death/discharge to hospice (adjusted odds ratio, 0.78 [95% CI, 0.72-0.85]), but no difference in discharge functional score, ambulatory status, or discharge home versus direct-admission patients.
conclusionsTransfer patients with anticoagulation-associated intracerebral hemorrhage had longer times to reversal at the admitting hospital, less severe intracerebral hemorrhage, and lower odds of in-hospital death versus direct-admission patients after adjustment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.